Phreesia, Inc. (NYSE:PHR – Get Free Report) gapped down prior to trading on Thursday after Canaccord Genuity Group lowered their price target on the stock from $46.00 to $43.00. The stock had previously closed at $30.00, but opened at $26.77. Canaccord Genuity Group currently has a buy rating on the stock. Phreesia shares last traded at $24.91, with a volume of 344,030 shares traded.
PHR has been the topic of a number of other research reports. Robert W. Baird cut their price target on shares of Phreesia from $40.00 to $39.00 in a research report on Thursday. Citigroup dropped their price objective on Phreesia from $40.00 to $37.00 and set a “buy” rating on the stock in a research note on Thursday. Royal Bank of Canada decreased their target price on Phreesia from $33.00 to $29.00 and set a “sector perform” rating for the company in a research note on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price target on shares of Phreesia in a research note on Thursday. Finally, KeyCorp reduced their price objective on shares of Phreesia from $45.00 to $40.00 in a research report on Thursday, May 25th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.
Check Out Our Latest Analysis on PHR
Insider Buying and Selling
Hedge Funds Weigh In On Phreesia
A number of hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC lifted its position in shares of Phreesia by 86.7% during the second quarter. Jennison Associates LLC now owns 2,571,842 shares of the company’s stock valued at $79,753,000 after purchasing an additional 1,194,479 shares in the last quarter. Granahan Investment Management LLC lifted its position in shares of Phreesia by 108.2% during the 1st quarter. Granahan Investment Management LLC now owns 1,487,265 shares of the company’s stock worth $48,024,000 after buying an additional 772,923 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in shares of Phreesia in the 2nd quarter worth approximately $13,668,000. BlackRock Inc. grew its holdings in shares of Phreesia by 5.8% in the first quarter. BlackRock Inc. now owns 6,359,641 shares of the company’s stock valued at $167,640,000 after acquiring an additional 349,301 shares in the last quarter. Finally, Lazard Asset Management LLC grew its holdings in shares of Phreesia by 102.5% in the first quarter. Lazard Asset Management LLC now owns 654,294 shares of the company’s stock valued at $17,247,000 after acquiring an additional 331,209 shares in the last quarter. Institutional investors and hedge funds own 94.37% of the company’s stock.
Phreesia Stock Down 22.1 %
The stock has a 50-day moving average of $29.53 and a 200 day moving average of $31.35. The company has a quick ratio of 2.89, a current ratio of 2.89 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.27 billion, a PE ratio of -7.70 and a beta of 0.63.
Phreesia (NYSE:PHR – Get Free Report) last released its earnings results on Wednesday, September 6th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03. The company had revenue of $85.80 million for the quarter, compared to analysts’ expectations of $85.26 million. Phreesia had a negative return on equity of 53.25% and a negative net margin of 53.89%. The business’s revenue for the quarter was up 26.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.89) EPS. Sell-side analysts anticipate that Phreesia, Inc. will post -2.69 EPS for the current year.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles
- Five stocks we like better than Phreesia
- Roth IRA Calculator: Calculate Your Potential Returns
- These 3 Wood Stocks are about to go on Discount
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
- The How and Why of Investing in Large-Cap Stocks
- 3 Stocks Awaiting Winter Winds of Opportunity
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.
